Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRIPTORELIN for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where TRIPTORELIN was used for Neoplasm malignant.

Most Reported Side Effects for TRIPTORELIN

Side Effect Reports % Deaths Hosp.
Off label use 545 10.1% 13 67
Death 362 6.7% 359 36
Ovarian hyperstimulation syndrome 356 6.6% 3 307
Needle issue 242 4.5% 6 2
Disease progression 203 3.8% 20 6
Product dose omission issue 178 3.3% 6 27
Drug ineffective 175 3.3% 9 13
Weight increased 167 3.1% 5 13
Hot flush 153 2.8% 7 20
Headache 145 2.7% 0 21
Injection site pain 138 2.6% 0 10
Inappropriate schedule of product administration 131 2.4% 29 55
Incorrect dose administered 131 2.4% 4 6
Syringe issue 128 2.4% 0 1
Vaginal haemorrhage 125 2.3% 3 12

Other Indications for TRIPTORELIN

Product used for unknown indication (1,867) Prostate cancer (1,485) Precocious puberty (277) Breast cancer (235) Assisted reproductive technology (175) Prostate cancer metastatic (146) Gender dysphoria (136) In vitro fertilisation (129) Ovulation induction (73) Off label use (61)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

TRIPTORELIN Full Profile All Neoplasm malignant Drugs TRIPTORELIN Demographics TRIPTORELIN Timeline